{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:01:32Z","timestamp":1773741692279,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,7]]},"DOI":"10.7759\/cureus.55719","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:18:45Z","timestamp":1709817525000},"source":"Crossref","is-referenced-by-count":2,"title":["Checkpoint Inhibitor-Related Capillary Leak Syndrome (CLS)"],"prefix":"10.7759","author":[{"given":"Ahmad","family":"Raja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Daniyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamm","family":"Polani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-5. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.11.029","article-title":"Capillary leak syndrome: etiologies, pathophysiology, and management","volume":"92","author":"Siddall E","year":"2017","unstructured":"Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017, 92:37-46. 10.1016\/j.kint.2016.11.029","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-020-02474-4","article-title":"Targeted intravenous nanoparticle delivery: role of flow and endothelial glycocalyx integrity","volume":"48","author":"Cheng MJ","year":"2020","unstructured":"Cheng MJ, Mitra R, Okorafor CC, et al.. Targeted intravenous nanoparticle delivery: role of flow and endothelial glycocalyx integrity. Ann Biomed Eng. 2020, 48:1941-54. 10.1007\/s10439-020-02474-4","journal-title":"Ann Biomed Eng"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110418","article-title":"Systemic capillary leak syndrome (clarkson syndrome) in cancer patients: a systematic review","volume":"7","author":"Shin JI","year":"2018","unstructured":"Shin JI, Lee KH, Lee IR, et al.. Systemic capillary leak syndrome (clarkson syndrome) in cancer patients: a systematic review. J Clin Med. 2018, 7:10.3390\/jcm7110418","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2022.11.001","article-title":"Immune checkpoint inhibitors-induced systemic capillary leak syndrome: a report of two cases","volume":"44","author":"Petitdemange A","year":"2023","unstructured":"Petitdemange A, B\u00e9guin L, Dimitrov Y. Immune checkpoint inhibitors-induced systemic capillary leak syndrome: a report of two cases. Rev Med Interne. 2023, 44:35-7. 10.1016\/j.revmed.2022.11.001","journal-title":"Rev Med Interne"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer JR","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al.. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020143","article-title":"Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis","volume":"8","author":"Jeong GH","year":"2019","unstructured":"Jeong GH, Lee KH, Lee IR, et al.. Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J Clin Med. 2019, 8:10.3390\/jcm8020143","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2021.01.004","article-title":"Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction","volume":"5","author":"Qin H","year":"2021","unstructured":"Qin H, Vlaminck B, Owoyemi I, Herrmann SM, Leung N, Markovic SN. Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction. Mayo Clin Proc Innov Qual Outcomes. 2021, 5:670-4. 10.1016\/j.mayocpiqo.2021.01.004","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100491","article-title":"Capillary leak syndrome with pulmonary edema preceded by organizing pneumonia caused by combination therapy with nivolumab and ipilimumab: a case report","volume":"4","author":"Tachi H","year":"2023","unstructured":"Tachi H, Shibagaki A, Teshima S, Hanazawa M, Matsukura S, Shimizu K, Yamamoto Y. Capillary leak syndrome with pulmonary edema preceded by organizing pneumonia caused by combination therapy with nivolumab and ipilimumab: a case report. JTO Clin Res Rep. 2023, 4:100491. 10.1016\/j.jtocrr.2023.100491","journal-title":"JTO Clin Res Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0335","article-title":"Nivolumab-induced systemic capillary leak syndrome as an ultra\u00a0rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy","volume":"13","author":"Polishchuk I","year":"2021","unstructured":"Polishchuk I, Yakobson A, Zemel M, et al.. Nivolumab-induced systemic capillary leak syndrome as an ultra\u00a0rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy. Immunotherapy. 2021, 13:807-11. 10.2217\/imt-2020-0335","journal-title":"Immunotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/231369-checkpoint-inhibitor-related-capillary-leak-syndrome-cls","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:18:49Z","timestamp":1709817529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/231369-checkpoint-inhibitor-related-capillary-leak-syndrome-cls"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.55719","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}